Skip to main content
Passa alla visualizzazione normale.

CIRINO BOTTA

Elotuzumab plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

  • Authors: Bruzzese, Antonella; Derudas, Daniele; Galli, Monica; Martino, Enrica Antonia; Rocco, Stefano; Conticello, Concetta; Califano, Catello; Giuliani, Nicola; Mangiacavalli, Silvia; Farina, Giuliana; Lombardo, Alessandra; Brunori, Marino; Rossi, Elena; Antonioli, Elisabetta; Ria, Roberto; Zambello, Renato; Di Renzo, Nicola; Mele, Giuseppe; Marcacci, Gianpaolo; Pietrantuono, Giuseppe; Palumbo, Gaetano; Cascavilla, Nicola; Cerchione, Claudio; Belotti, Angelo; Criscuolo, Clelia; Uccello, Giuseppina; Curci, Paola; Vigna, Ernesto; Mendicino, Francesco; Iaccino, Enrico; Mimmi, Selena; Botta, Cirino; Vincelli, Donatella; Sgherza, Nicola; Bonalumi, Angela; Cupelli, Luca; Stocchi, Raffaella; Martino, Massimo; Ballanti, Stelvio; Gangemi, Dominella; Gagliardi, Alfredo; Gamberi, Barbara; Pompa, Alessandra; Tripepi, Giovanni; Frigeri, Ferdinando; Consoli, Ugo; Bringhen, Sara; Zamagni, Elena; Patriarca, Francesca; De Stefano, Valerio; Di Raimondo, Francesco; Palmieri, Salvatore; Petrucci, Maria Teresa; Offidani, Massimo; Musto, Pellegrino; Boccadoro, Mario; Cavo, Michele; Neri, Antonino; Morabito, Fortunato; Gentile, Massimo
  • Publication year: 2022
  • Type: Articolo in rivista
  • OA Link: http://hdl.handle.net/10447/558509

Abstract

: The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM). The present study is a 3-year follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloRd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow-up of 36 months (range 6-55), 236 patients experienced disease progression or died. Median progression-free survival (PFS) and overall survival (OS) were 18.4 and 34 months, respectively. The updated multivariate analyses showed a significant reduction of PFS and OS benefit magnitude only in cases with ISS stage III. Major adverse events included grade 3/4 neutropenia (18.5%), anemia (15.4%), lymphocytopenia (12.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 33.9% and 18.9%, respectively. No new safety signals with longer follow-up have been observed. Of 319 patients, 245 (76.7%) reached at least a partial remission. A significantly lower response rate was found in patients previously exposed to lenalidomide. In conclusion, our study confirms that EloRd is a safe and effective regimen for RRMM patients, maintaining benefits across multiple unfavorable subgroups. This article is protected by copyright. All rights reserved.